Objective  To conduct a comparative analysis of research trends and hotspots in the management of narcotic and psychotropic drugs based on CiteSpace, and to provide references for the development of narcotic and psychotropic drug management in China.

Methods  Relevant literature on the management of narcotic and psychotropic drugs was retrieved from databases such as CNKI, VIP, WanFang, Web of Science, and PubMed, with a search timeframe from January 1, 2019, to December 31, 2024. CiteSpace 6.4.R1 software was used to visualize and analyze the publishing countries, author collaborations, keyword co-occurrences, clusters, and bursts of the literature related to the management of narcotic and psychotropic drugs.

Results  The study included 870 Chinese articles and 1,194 English articles. The highest number of English publications was in 2024 (286 articles), showing an overall upward trend with increasing years. The peak of Chinese publications was in 2020 (198 artilces), followed by a yearly decline. The United States ranked first in terms of English publications (107 articles), while China ranked second (27 articles). Collaboration among publishing countries and authors was relatively scarce. The top three Chinese co-occurrence keywords were "inpatient pharmacy" "prescription review" and "outpatient clinic"; the top three English co-occurrence keywords were "acute pain" "cancer pain" and "emergency service".

Conclusion  Chinese literature focuses on research on prescription management and intelligent closed-loop drug management, while English literature pays more attention to emergency services and postoperative analgesia. Chinese research integrates clinical needs into management upgrades, while English research supplements management techniques in clinical applications, jointly promoting global management of narcotic and psychotropic drugs.

1.满春霞, 邹武捷, 杨淑苹, 等. 麻醉药品和精神药品管制研究Ⅴ——国内外麻醉药品和精神药品的管制制度比较研究[J]. 中国药房, 2017, 28(1): 23-26. [Man CX, Zou WJ, Yang SP, et al. study on narcotics and psychotropic substances control (part  Ⅴ): comparative study on domestic and foreign control system of narcotics and psychotropic substances[J]. China Pharmacy, 2017, 28(1): 23-26.] DOI: 10.6039/j.issn.1001-0408.2017.01.06.

2.王燕. 麻醉药品、第一类精神药品的使用和管理中存在的问题与对策探讨[J]. 中国医药指南, 2016, 14(19): 283. [Wang  Y. Discussion on the problems and countermeasures in the use and management of anesthetic drugs and first-class psychotropic drugs[J]. Chinese Medical Guide, 2016, 14(19): 283.] DOI: 10.15912/j.cnki.gocm.2016.19.241.

3.刘小勤, 李宗恩, 李阳阳. 中美比较视野下中国精神药品管制问题研究[J]. 医学与法学, 2021, 13(4): 48-52. [Liu XQ, Li ZE, Li YY. Study on the control of psychotropic substances in China from the perspective of comparison between china and the United States[J]. Medicine and Jurisprudence, 2021, 13(4): 48-52.] DOI: 10.3969/j.issn.1674-7526.2021.04.009.

4.谢菡, 叶孝, 游一中, 等. 中英两国医疗机构麻醉药品和精神药品管理政策对比[J]. 中国药师, 2020, 23(8): 1605-1608. [Xie H, Ye X, You YZ, et al. Comparative analysis of anesthetic drugs and psychotropic drugs management policies in medical institutions of China and the United Kingdom[J]. Chinese Journal of Pharmacy, 2020, 23(8): 1605-1608.] DOI: 10.3969/j.issn.1008-049X.2020.08.032.

5.Zhong D, Li Y, Huang Y, et al. Molecular mechanisms of exercise on cancer: a bibliometrics study and visualization analysis via CiteSpace[J]. Front Mol Biosci, 2022, 8: 797902. DOI: 10.3389/fmolb.2021.797902.

6.秦珺, 郁文刘, 陈蓉. 基于CiteSpace的国内外门诊患者药学服务研究热点及前沿的可视化分析[J]. 中国医院药学杂志, 2024, 44(19): 2281-2288, 2293. [Qin J, Yu WL, Chen R. CiteSpace-based visualization analysis of research hotspots and fronts of outpatient pharmaceutical care in China and at abroad[J]. Chinese Journal of Hospital Pharmacy, 2024, 44(19): 2281-2288, 2293.] DOI: 10.13286/j.1001-5213.2024.19.13.

7.覃旺军, 任夏洋, 李然, 等. 癌症疼痛管理药学专家共识 [J]. 中国疼痛医学杂志, 2019, 25(11): 801-807. [Qin WJ, Ren  XY, Li R, et al. Expert consensus on pharmacy in cancer pain management[J]. Chinese Journal of Pain Medicine, 2019, 25(11): 801-807.] DOI: 10.3969/j.issn.1006-9852.2019.11.001.

8.Brozović G, Lesar N, Janev D, et al. Cancer pain and therapy[J]. Acta Clin Croat, 2022, 61(Suppl 2): 103-108. DOI: 10.20471/acc.2022.61.s2.13.

9.Abdel Shaheed C, Hayes C, Maher CG, et al. Opioid analgesics for nociceptive cancer pain: a comprehensive review[J]. CA Cancer J Clin, 2023, 74(3): 286-313. DOI: 10.3322/caac.21823.

10.Chapman EJ, Edwards Z, Boland JW, et al. Practice review: evidence-based and effective management of pain in patients with advanced cancer[J]. Palliat Med, 2020, 34(4): 444-453. DOI: 10.1177/0269216319896955.

11.苗笛, 王蕾. 基于品管圈提高门急诊麻醉药品精神药品处方合格率的应用分析[J]. 中国药物与临床, 2025, 25(10): 673-677. [Miao D, Wang L. Application analysis of enhancing compliance rates for anesthetic and psychotropic drug prescriptions in outpatient and emergency departments via quality control circle[J]. Chinese Remedies & Clinics, 2025, 25(10): 673-677.] DOI: 10.11655/zgywylc2025.10.011.

12.陈美平. PDCA循环法在麻精药品处方规范化管理中的应用价值分析[J]. 北方药学, 2023, 20(5): 56-58. [Chen MP. Analysis of the application value of PDCA cycle method in the standardized management of psychotropic drugs prescriptions[J]. Journal of North Pharmacy, 2023, 20(5): 56-58.] DOI: 10.3969/j.issn.1672-8351.2023.05.019.

13.赵子玮. PDCA循环法在麻精药品规范化管理中的应用效果分析[J]. 中国现代药物应用, 2024, 18(6): 153-155. [Zhao  ZW. Application effect analysis of PDCA cycle in standardized management of anesthetics and psychotropic drugs[J]. Chinese Journal of Modern Drug Application, 2024, 18(6): 153-155.] DOI: 10.14164/j.cnki.cn11-5581/r.2024.06.040.

14.胡晓. 门诊麻精药品不合理处方分析[J]. 中国卫生标准管理, 2021, 12(21): 88-91. [Hu X. Analysis of irrational prescriptions of narcotic drugs and first-class psychotropic drugs in outpatient clinics[J]. China Health Standard Management, 2021, 12(21): 88-91.] DOI: 10.3969/j.issn.1674-9316.2021.21.029.

15.梁颖红, 冯娟, 徐艳苹. 门诊麻醉药品处方分析及有效管理措施探讨[J]. 中国处方药, 2022, 20(8): 47-49. [Liang  YH, Feng  J, Xu YP. Analysis of outpatient anesthetic drug prescriptions and discussion on effective management measures[J]. Journal of China Prescription Drug, 2022, 20(8): 47-49.] DOI: 10.3969/j.issn.1671-945X.2022.08.015.

16.中国抗癌协会肿瘤临床药学专业委员会, 医疗机构麻醉药品和第一类精神药品信息化管理专家共识编写组. 医疗机构麻醉药品和第一类精神药品信息化管理专家共识[J]. 医药导报, 2022, 41(1): 1-7. [China Anti-Cancer Association, Committee of Clinical Pharmacy of Oncology. Expert Consensus Writing Group on Information Management of Anesthetic Drugs and Category I Psychotropic Substances in Medical Institutions. Expert Consensus on the information management of anesthetic drugs and category i psychotropic substances in medical institutions[J]. Herald of Medicine, 2022, 41(1): 1-7.] DOI: 10.3870/j.issn.1004-0781.2022.01.001.

17.史香芬, 孙志勇, 张旭锋, 等. 基于智能信息管理系统的门诊麻精药品全流程管理[J]. 中国药物警戒, 2023, 20(8): 899-903. [Shi XF, Sun ZY, Zhang XF, et al. Whole process management of narcotic drugs and psychotropic drugs based on intelligent information management system[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 899-903.] DOI: 10.19803/j.1672-8629.20220176.

18.邢雪燕, 张欢, 晁会, 等. 基于HIS系统的麻精药品闭环管理[J]. 麻醉安全与质控, 2021, 5(2): 97-99. [Xing XY, Zhang H, Zhao H, et al. Closed-loop management of narcotic and psychotropic drugs based on HIS system[J]. Perioperative Safety and Quality Assurance, 2021, 5(2): 97-99.] DOI: 10.3969/j.issn.2096-2681.2021.02.007.

19.邢鲁民, 徐民, 李潇. 智能化药品闭环管理在药品管理流程优化的应用体会[J]. 中国医学装备, 2019, 16(4): 137-141. [Xing LM, Xu M, Li X. Experience of application of intelligent drug closed-loop management in optimization of drug management process[J]. China Medical Equipment, 2019, 16(4): 137-141.] DOI: 10.3969/J.ISSN.1672-8270.2019.04.038.

20.戎成婷, 王菲菲, 罗晶晶, 等. 麻醉精神类药品智能管理系统的构建与应用[J]. 中国卫生质量管理, 2023, 30(2): 16-19. [Rong CT, Wang FF, Luo JJ, et al. Development and application of intelligent management system for narcotic and psychotropic drugs[J]. Chinese Health Quality Management, 2023, 30(2): 16-19.] DOI: 10.13912/j.cnki.  chqm.2023.30.2.05.

21.陈韵光, 黄剑, 钱莉, 等. 智能药车辅助下精麻药品闭环管理的“中山模式”[J]. 复旦学报（医学版）, 2023, 50(2): 243-248, 254. [Chen YG, Huang J, Qian L, et al. "Zhongshan Model" closed-loop management of narcotic and psychotropic drugs assisted by the intelligent medicine cabinet[J]. Fudan University Journal of Medical Sciences, 2023, 50(2): 243-248, 254.] DOI: 10.3969/j.issn.1672-8467.2023.02.013.

22.Punches BE, Soliman S, Freiermuth CE et al. Emergency nurse perceptions of naloxone distribution in the emergency department[J]. J Emerg Nurs, 2020, 46(5): 675-681.e1. DOI: 10.1016/j.jen.2020.05.006.  

23.Carroll GG, Wasserman DD, Shah AA, et al. Buprenorphine field initiation of rescue treatment by emergency medical services (Bupe FIRST EMS): a case series[J]. Prehosp Emerg Care, 2021, 25(2): 289-293. DOI: 10.1080/10903127.2020.1747579.

24.Gabriel RA, Swisher MW, Sztain JF, et al. State of the art opioid-sparing strategies for post-operative pain in adult surgical patients[J]. Expert Opin Pharmacother, 2019, 20(8): 949-961. DOI: 10.1080/14656566.2019.1583743.

25.Sangkum L, Tangjitbampenbun A, Chalacheewa T, et al. Peripheral nerve blocks for cesarean delivery analgesia: a narrative review[J]. Medicina (Kaunas), 2023, 59(11): 1951. DOI: 10.3390/medicina59111951.

26.Bischoff M, Graf BM, Redel A. Perioperative management of concomitant medication[J]. Fortbildung, 2019, 60: 560-571. DOI: 10.19224/ai2019.560.